Respiratory clinical trials
Expertise in pulmonary research
The first treatment of its kind is here—
because they trusted Rho to get it done.
The Pulmonary Progression Model:
Advancing Science, One Breath at a Time
Respiratory diseases impact millions worldwide, affecting not just lung function, but quality of life. At Rho, we bring a deep understanding of pulmonary conditions, a commitment to rigorous clinical research, and a focus on improving patient outcomes. Whether tackling asthma, COPD, or rare respiratory diseases, we partner with you to design and execute trials that move science—and hope—forward.
Why Rho?
Why Rho?
Specialized respiratory expertise
Adaptive trial design
Seamless regulatory navigation
Patient-centered approach
Spotlight: Advancing cystic fibrosis research
Cystic fibrosis (CF) remains one of the most challenging respiratory conditions, requiring innovative approaches and dedicated expertise. Rho has contributed to groundbreaking CF research, playing a vital role in trials that have led to FDA-approved therapies improving lung function and patient outcomes. Our deep involvement in CF studies includes:
- Optimizing trial design for CF therapies – Experience with phase 1-3 trials, including novel triple-combination therapies that have redefined treatment paradigms.
- Advanced biomarker and endpoint integration – Expertise in sweat chloride testing, lung function assessments (FEV1), and patient-reported outcomes.
- Regulatory strategy and rare disease experience – Successfully guiding CF treatments through FDA’s expedited pathways, including Fast Track and Breakthrough Therapy designations.
- Decades of CF research experience – Trusted by leading sponsors and academic collaborators, we’ve supported more than 30 CF studies across all phases, including pivotal trials with the Cystic Fibrosis Foundation, contributing to the advancement of CF therapies worldwide.
Cystic fibrosis (CF) remains one of the most challenging respiratory conditions, requiring innovative approaches and dedicated expertise. Rho has played a key role in CF clinical trials, helping to advance therapies that improve lung function and extend quality of life. Our experience includes:
- Cutting-edge trial design – Incorporating novel endpoints to measure therapeutic impact more effectively.
- Regulatory expertise – Navigating FDA and global agency expectations for CF-specific treatments.
- Real-world impact – Supporting research that leads to actionable, life-changing treatments for the CF community.
Spotlight: Advancing cystic fibrosis research
Cystic fibrosis (CF) remains one of the most challenging respiratory conditions, requiring innovative approaches and dedicated expertise. Rho has contributed to groundbreaking CF research, playing a vital role in trials that have led to FDA-approved therapies improving lung function and patient outcomes. Our deep involvement in CF studies includes:
- Optimizing trial design for CF therapies – Experience with phase 1-3 trials, including novel triple-combination therapies that have redefined treatment paradigms.
- Advanced biomarker and endpoint integration – Expertise in sweat chloride testing, lung function assessments (FEV1), and patient-reported outcomes.
- Regulatory strategy and rare disease experience – Successfully guiding CF treatments through FDA’s expedited pathways, including Fast Track and Breakthrough Therapy designations.
- Decades of CF research experience – Trusted by leading sponsors and academic collaborators, we’ve supported more than 30 CF studies across all phases, including pivotal trials with the Cystic Fibrosis Foundation, contributing to the advancement of CF therapies worldwide.
Cystic fibrosis (CF) remains one of the most challenging respiratory conditions, requiring innovative approaches and dedicated expertise. Rho has played a key role in CF clinical trials, helping to advance therapies that improve lung function and extend quality of life. Our experience includes:
- Cutting-edge trial design – Incorporating novel endpoints to measure therapeutic impact more effectively.
- Regulatory expertise – Navigating FDA and global agency expectations for CF-specific treatments.
- Real-world impact – Supporting research that leads to actionable, life-changing treatments for the CF community.
Respiratory FAQ
What respiratory conditions does Rho specialize in?
Rho has expertise in trials for asthma, COPD, rare pulmonary diseases, and respiratory infections. We specialize in designing trials tailored to respiratory endpoints and patient populations.
What makes respiratory clinical trials complex?
Respiratory trials often involve intricate endpoint measures, diverse patient populations, and environmental considerations. Rho’s experience with respiratory studies helps sponsors address these challenges with innovative trial strategies.
How does Rho support patient recruitment for
respiratory trials?
Recruiting for respiratory trials can be challenging due to seasonal variations and specific inclusion criteria. Rho leverages strong site relationships, and targeted engagement strategies to boost enrollment.
Does Rho have experience with rare pulmonary
disease trials?
Comprehensive support for respiratory
clinical trials
We provide full-service support across all phases of respiratory research:
Asthma and COPD studies
Rare pulmonary disease research
Pulmonary function testing and biomarkers
Regulatory strategy and submissions
Real-world evidence and long-term outcomes
Meet the
team
who make
it happen
Related insights & resources
Ready to move respiratory research forward? Let’s work together to bring better treatments to those who need them most.
